189 related articles for article (PubMed ID: 24487790)
1. Prognostic prostate tissue biomarkers of potential clinical use.
Van der Kwast TH
Virchows Arch; 2014 Mar; 464(3):293-300. PubMed ID: 24487790
[TBL] [Abstract][Full Text] [Related]
2. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy.
Brown JA; Slezak JM; Lieber MM; Jenkins RB
Mayo Clin Proc; 1999 Dec; 74(12):1214-20. PubMed ID: 10593349
[TBL] [Abstract][Full Text] [Related]
4. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
5. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.
Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A
Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165
[TBL] [Abstract][Full Text] [Related]
6. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.
Renard Penna R; Cancel-Tassin G; Comperat E; Mozer P; Léon P; Varinot J; Roupret M; Bitker MO; Lucidarme O; Cussenot O
World J Urol; 2016 Oct; 34(10):1389-95. PubMed ID: 26902878
[TBL] [Abstract][Full Text] [Related]
7. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
8. Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients.
Savio AJ; Kamdar S; Jeyapala R; Olkhov-Mitsel E; Cuizon C; Finelli A; Zlotta AR; Toi A; Fleshner NE; van der Kwast T; Bapat B
J Mol Diagn; 2020 Jan; 22(1):30-39. PubMed ID: 31605802
[TBL] [Abstract][Full Text] [Related]
9. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
[TBL] [Abstract][Full Text] [Related]
10. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
11. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
12. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
17. Markers and meaning of primary treatment failure.
Swindle PW; Kattan MW; Scardino PT
Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
[TBL] [Abstract][Full Text] [Related]
18. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
19. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
